New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Nexalin Technology (NXL) announces validation of its Deep Intracranial Frequency Stimulation (DIFS) technology in a new peer-reviewed editorial published in Psychotherapy and Psychosomatics. The company's 15mA DIFS technology demonstrates superior deep brain penetration compared to traditional neurostimulation methods, effectively reaching critical areas like the hippocampus, amygdala, and insula. The neuromodulation market is projected to reach $11.0 billion by 2028.
The publication validates DIFS's ability to non-invasively treat psychiatric conditions like major depressive disorder and chronic insomnia, offering a safer alternative to invasive procedures while providing tailored neuromodulation for different conditions.
Nexalin Technology (NXL) annuncia la validazione della sua tecnologia di Stimolazione Frequenziale Profonda Intracranica (DIFS) in un nuovo editoriale sottoposto a revisione paritaria pubblicato su Psychotherapy and Psychosomatics. La tecnologia DIFS da 15mA dell'azienda dimostra una penetrazione nel cervello profonda superiore rispetto ai metodi tradizionali di neurostimolazione, raggiungendo efficacemente aree critiche come ippocampo, amigdala e insula. Si prevede che il mercato della neuromodulazione raggiungerà 11,0 miliardi di dollari entro il 2028.
La pubblicazione convalida la capacità del DIFS di trattare in modo non invasivo condizioni psichiatriche come il disturbo depressivo maggiore e l'insonnia cronica, offrendo un'alternativa più sicura rispetto alle procedure invasive, fornendo nel contempo una neuromodulazione personalizzata per diverse condizioni.
Nexalin Technology (NXL) anuncia la validación de su tecnología de Estimulación de Frecuencia Intracraneal Profunda (DIFS) en un nuevo editorial revisado por pares publicado en Psychotherapy and Psychosomatics. La tecnología DIFS de 15mA de la compañía muestra una penetración cerebral profunda superior en comparación con los métodos tradicionales de neuroestimulación, alcanzando eficazmente áreas críticas como el hipocampo, la amígdala y la ínsula. Se proyecta que el mercado de la neuromodulación alcanzará los 11,0 mil millones de dólares para 2028.
La publicación valida la capacidad del DIFS para tratar de manera no invasiva condiciones psiquiátricas como el trastorno depresivo mayor y el insomnio crónico, ofreciendo una alternativa más segura a los procedimientos invasivos, al mismo tiempo que proporciona una neuromodulación personalizada para diferentes condiciones.
Nexalin Technology (NXL)는 Psychotherapy and Psychosomatics에 게재된 새로운 동료 심사 편집글을 통해 깊은 두개내 주파수 자극(DIFS) 기술의 검증을 발표했습니다. 회사의 15mA DIFS 기술은 기존의 신경 자극 방법에 비해 우수한 깊은 뇌 침투력을 보여주며, 해마, 편도체, 섬엽과 같은 중요한 영역에 효과적으로 도달합니다. 신경 조절 시장은 2028년까지 110억 달러에 이를 것으로 예상됩니다.
이 출판물은 DIFS가 주요 우울 장애 및 만성 불면증과 같은 정신적 조건을 비침습적으로 치료할 수 있는 능력을 검증하며, 침습적 절차에 비해 더 안전한 대안을 제공하고 다양한 조건에 맞춘 개별화된 신경 조절을 제공합니다.
Nexalin Technology (NXL) annonce la validation de sa technologie de stimulation de fréquence intracrânienne profonde (DIFS) dans un nouvel éditorial évalué par des pairs publié dans Psychotherapy and Psychosomatics. La technologie DIFS de 15mA de l'entreprise démontre une pénétration cérébrale profonde supérieure par rapport aux méthodes de neurostimulation traditionnelles, atteignant efficacement des zones critiques telles que l'hippocampe, l'amygdale et l'insula. Le marché de la neuromodulation devrait atteindre 11,0 milliards de dollars d'ici 2028.
La publication valide la capacité de DIFS à traiter de manière non invasive des conditions psychiatriques telles que le trouble dépressif majeur et l'insomnie chronique, offrant une alternative plus sûre aux procédures invasives tout en fournissant une neuromodulation personnalisée pour différentes conditions.
Nexalin Technology (NXL) gibt die Validierung seiner tiefen intrakranialen Frequenzstimulation (DIFS) Technologie in einem neuen, peer-reviewed Editorial in Psychotherapy and Psychosomatics bekannt. Die 15mA DIFS Technologie des Unternehmens zeigt eine überlegene tiefen Hirnpenetration im Vergleich zu traditionellen Neurostimulationsmethoden und erreicht effektiv kritische Bereiche wie den Hippocampus, die Amygdala und die Insula. Der Neuromodulationsmarkt wird bis 2028 auf 11,0 Milliarden Dollar geschätzt.
Die Veröffentlichung validiert die Fähigkeit von DIFS, psychiatrische Erkrankungen wie major depressive disorder und chronische Schlaflosigkeit nicht-invasiv zu behandeln, und bietet eine sichere Alternative zu invasiven Verfahren, während sie gleichzeitig maßgeschneiderte Neuromodulation für verschiedene Erkrankungen bereitstellt.
- Technology validation through peer-reviewed publication
- Superior deep brain penetration capability compared to competitors
- Positioned in $11.0 billion neuromodulation market by 2028
- Non-invasive treatment alternative with lower risks
- Scalable technology offering tailored treatment intensities
- None.
Insights
This peer-reviewed validation of Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology represents a significant scientific milestone. The 15mA DIFS system demonstrates superior deep brain penetration compared to existing tACS and tDCS technologies, reaching critical regions like the hippocampus, amygdala and insula. The stereoelectroencephalography (SEEG) evidence supporting these claims adds substantial credibility.
The technology's potential market impact is bolstered by its positioning in the
The publication validates Nexalin's competitive positioning in the neuromodulation market, particularly for treating major depressive disorder (MDD) and chronic insomnia. With a relatively small market cap of
The technology's differentiation through superior deep brain penetration and non-invasive approach creates a compelling value proposition. However, investors should note that market success will depend on factors beyond technical validation, including reimbursement policies, clinical adoption rates and competition from established medical device companies. The peer-reviewed publication adds credibility but commercialization challenges remain.
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment
HOUSTON, TX, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announces that its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology is prominently featured in a newly published editorial in Psychotherapy and Psychosomatics. This peer-reviewed article provides compelling validation of Nexalin’s ability to non-invasively treat challenging psychiatric conditions, highlighting the Company’s unique positioning in the rapidly growing neuromodulation market, which is projected to reach
The editorial underscores the advantages of the Company’s 15mA DIFS over traditional neurostimulation and neuromodulation devices. Unlike low-intensity transcranial alternating current stimulation (tACS) or low-intensity transcranial direct current stimulation (tDCS), which lack sufficient power to reach deeper brain regions, Nexalin’s technology delivers high-intensity frequency-based stimulation capable of activating critical areas such as the hippocampus, amygdala, and insula. Supported by stereoelectroencephalography (SEEG) recordings, the findings described in the editorial support the Company’s ability to address previously unmet needs in treating conditions like major depressive disorder (MDD), chronic insomnia and other mental health issues.
“This publication provides robust validation of Nexalin’s technology from a scientific perspective and reinforces the Company’s ability to address significant gaps in the mental health market,” said Dr. David Owens, Chief Medical Officer at Nexalin Technology. “By effectively reaching deep brain regions non-invasively, Nexalin’s DIFS technology has the potential to become a cornerstone in treatment paradigms for psychiatric disorders.”
Key insights from the publication include:
- Deep Brain Penetration: Unlike traditional devices, the Company’s 15mA DIFS achieves significant activation of deep brain regions critical for mental health treatment, far surpassing the reach of low-intensity devices.
- Tailored Neuromodulation: The article validates that different psychiatric conditions benefit from varying stimulation intensities, a need the Company’s scalable technology uniquely addresses.
- Safety and Accessibility: The Company’s technology has the potential to offer a powerful, non-invasive alternative to costly and risk-laden procedures like deep brain stimulation (DBS) or focused ultrasound.
Mark White, CEO of Nexalin Technology, added, “This publication marks an important milestone as we continue to execute our strategic plan to bring Nexalin’s DIFS technology to market. Our technology’s ability to deliver deep brain stimulation non-invasively not only validates its clinical potential but also strengthens our competitive position in a rapidly expanding industry. We are confident this will drive value for patients and investors alike.”
The editorial further highlights the shortcomings of traditional neuromodulation methods, emphasizing the Company’s competitive advantages in safety, efficacy, and market potential. With this validation, the Company’s goal is to capture a significant share of the growing neuromodulation market, aligning with broader trends in healthcare innovation and precision medicine.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What is the projected market size for Nexalin's (NXL) neuromodulation technology by 2028?
How does Nexalin's (NXL) DIFS technology differ from traditional neurostimulation methods?
What medical conditions can Nexalin's (NXL) DIFS technology treat?
